Artificial Intelligence for Non-Invasive Prediction of Molecular Signatures in Spinal Metastases: A Systematic Review

Background: Spinal metastases (SMs) are associated with poor prognosis and significant morbidity. We hypothesize that artificial intelligence (AI) models can enhance the identification and clinical utility of genetic and molecular signatures associated with SMs, improving diagnostic accuracy and enabling personalized treatment strategies. Methods: A systematic review of five databases was conducted to identify studies that used AI to predict genetic alterations and SMs outcomes. Accuracy, area under the receiver operating curve (AUC), and sensitivity were used for comparison. Data analysis was performed in R. Results: Eleven studies met the inclusion criteria, covering three different primary tumor origins, comprising a total of 2211 patients with an average of 201 ± 90 patients (range: 76–359 patients) per study. EGFR, Ki-67, and HER-2 were studied in ten (90.9%), two (18.1%), and one (9.1%) study, respectively. The weighted average AUC is 0.849 (95% CI: 0.835–0.863) and 0.791 (95% CI: 0.738–0.844) for internal and external validation of the established models, respectively. Conclusions: AI, through radiomics and machine learning, shows strong potential in predicting molecular markers in SMs. Our study demonstrates that AI can predict molecular markers in SMs with high accuracy.